Literature DB >> 11439172

Acute phase haemolysis in chronic cold agglutinin disease.

E Ulvestad1, S Berentsen, T E Mollnes.   

Abstract

We previously described a paradoxical form of chronic cold agglutinin disease (CAD) in which haemolysis occurred during episodes of fever but only marginally during exposure to colds. In order to investigate the molecular basis for this response we performed a 12-month prospective study of a patient with CAD and paradoxical haemolysis. Blood samples were collected monthly during health, and daily following hospitalization owing to hip fracture. During health we observed decreased levels of C3, undetectable C4, a non-functional classical pathway and a normal alternative pathway. Increased concentrations of C1-INH/C1rs complexes indicated continuous formation of C1-antibody-antigen complexes. There was a low-grade temperature-dependent fluctuating haemolysis as evidenced from measurements of lactate dehydrogenase. Following the hip fracture, the haemolysis increased. Levels of interleukin (IL)-1beta, IL-6, interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha increased as did C1-INH, C3, C4, CRP, and lactate dehydrogenase. The results support our hypothesis stating that paradoxical haemolysis in CAD is controlled by the availability of early classical pathway complement molecules and that haemolysis following acute phase responses occurs as a consequence of increased complement synthesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439172     DOI: 10.1046/j.1365-3083.2001.00960.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  12 in total

1.  Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.

Authors:  Eirik Tjønnfjord; Øystein A Vengen; Sigbjørn Berentsen; Geir Erland Tjønnfjord
Journal:  BMJ Case Rep       Date:  2017-05-09

Review 2.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Therapy for chronic cold agglutinin disease: perspective for further improvements.

Authors:  Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-01-22       Impact factor: 3.443

4.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

Review 5.  Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Authors:  Sigbjørn Berentsen; Tatjana Sundic
Journal:  Biomed Res Int       Date:  2015-01-29       Impact factor: 3.411

6.  Report of cold agglutinins in a patient with acute ischemic stroke.

Authors:  Haiqiang Jin; Wei Sun; Yongan Sun; Yining Huang; Yunchuang Sun
Journal:  BMC Neurol       Date:  2015-10-30       Impact factor: 2.474

Review 7.  Role of Complement in Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Transfus Med Hemother       Date:  2015-09-07       Impact factor: 3.747

Review 8.  New Insights in the Pathogenesis of Autoimmune Hemolytic Anemia.

Authors:  Wilma Barcellini
Journal:  Transfus Med Hemother       Date:  2015-09-07       Impact factor: 3.747

Review 9.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

10.  Acute exacerbation of cold agglutinin disease during operation.

Authors:  Jinyoung Jeong; Hye Kyoung Lee; Eun-Su Choi; Wonsik Ahn
Journal:  Korean J Anesthesiol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.